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Abstract
Aims To investigate the impact of baseline 1,5-anhydroglucitol on the treatment effect of basal–bolus therapy in people
with Type 2 diabetes.
Methods Post hoc analysis of onset 3, an 18-week, randomized, phase 3 trial evaluating the efficacy and safety of fast-
acting insulin aspart in basal–bolus therapy (n = 116) vs. basal insulin-only therapy (n = 120) in people with Type 2
diabetes. The estimated treatment difference in change from baseline in HbA1c was investigated for different cut-off
values of baseline 1,5-anhydroglucitol (2, 3, 4, 5 and 6 lg/ml).
Results The estimated treatment difference in change from baseline in HbA1c between basal–bolus therapy and basal
insulin-only therapy was statistically significantly greater in participants with baseline 1,5-anhydroglucitol ≤3 lg/ml
(n = 34) vs. >3 lg/ml (n = 198) [estimated treatment difference (95% CI): 1.53% (2.12; 0.94) vs. 0.82% (1.07;
0.57); P-value for interaction = 0.03]. The estimated treatment difference became more pronounced when comparing
participants with 1,5-anhydroglucitol ≤2 lg/ml (n = 15) vs. >2 lg/ml (n = 217) [estimated treatment difference (95%
CI): 2.26% (3.15; 1.36) vs. 0.85% (1.08; 0.62); P-value for interaction = 0.003]. For cut-off values ≥4 lg/ml,
estimated treatment differences were numerically greater below the cut-off compared with above, although the
interaction terms were not statistically significant.
Conclusion This analysis indicates that people with Type 2 diabetes with low 1,5-anhydroglucitol have an added
treatment benefit with basal–bolus therapy compared with people with higher 1,5-anhydroglucitol. Further research is
needed to clarify any clinical utility of these findings.
Clinical Trials Registry No: NCT01850615
Diabet. Med. 35, 1273–1278 (2018)
Introduction
Type 2 diabetes is characterized by insulin resistance and
impaired insulin secretion, resulting in both fasting and
postprandial hyperglycaemia. To control fasting plasma
glucose (FPG), treatment guidelines recommend initiating
basal insulin when HbA1c targets have not been achieved
with oral antidiabetes drugs [1]. While control of FPG is
necessary, it is usually insufficient for maintaining appropri-
ate HbA1c targets [2], and many people with Type 2 diabetes
will eventually benefit from treatment intensification with
drugs that target postprandial plasma glucose (PPG) excur-
sions (e.g. mealtime bolus insulin or glucagon-like peptide-1
receptor analogues). However, determining which people
with Type 2 diabetes would benefit from basal–bolus
therapy is a challenge facing physicians in clinical practice.
Plasma 1,5-anhydroglucitol (1,5-AG) has been proposed
as a marker to assess short-term glycaemic control in
people with Type 1 and Type 2 diabetes [3–5]. 1,5-AG is
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an endogenous dietary polyol, structurally similar to glu-
cose, that is maintained at a constant steady state in the
blood [6]. When blood glucose is in the normal range, 1,5-
AG is reabsorbed in the proximal tubules of the kidney and
is stable in the range of 6.8–29.3 lg/ml in women and 10.7–
32.0 lg/ml in men [4]. When blood glucose exceeds the
renal threshold (~180 mg/dl), glucose blocks reabsorption of
1,5-AG and circulating levels decrease. When glycaemic
control is restored, 1,5-AG levels recover at a rate of
~0.3 lg/ml per day. Consequently, 1,5-AG responds rapidly
to changes in blood glucose, and, in contrast to HbA1c, can
reflect glycaemic control over the previous 1–2 weeks [7,8].
The onset 3 trial was an 18-week, multicentre, open-label,
randomized phase 3 trial that evaluated the efficacy and
safety of fast-acting insulin aspart (faster aspart) in basal–
bolus therapy vs. basal insulin-only therapy in people with
Type 2 diabetes [9]. Faster aspart is a new formulation of
insulin aspart that presents with an earlier onset of appear-
ance, a higher early insulin exposure, and a greater early
glucose-lowering effect compared with conventional insulin
aspart [10]. In onset 3, as part of basal–bolus therapy, faster
aspart significantly reduced HbA1c compared with basal
insulin [estimated treatment difference (ETD) 95% confi-
dence interval (CI)]: 0.94% [1.17; 0.72]; P <0.0001.
The reduction in overall mean 2-h PPG and mean PPG
increment for all meals [derived from self-measured plasma
glucose (SMPG) values], and the increase in 1,5-AG were
also statistically significant in favour of basal–bolus therapy
compared with basal insulin-only therapy [9].
In the current analysis, it was hypothesized that the
treatment effect of basal–bolus therapy would be different in
people with Type 2 diabetes and low baseline 1,5-AG
compared with people with Type 2 diabetes and high
baseline 1,5-AG (i.e. that baseline 1,5-AG would be predic-
tive of the basal–bolus treatment effect). This hypothesis was
explored using data from onset 3 to perform a post hoc
analysis of the treatment differences within subgroups based
on baseline 1,5-AG.
Participants and methods
onset 3 design
The onset 3 methodology has been reported previously [9].
The trial compared intensification with faster aspart in a
basal–bolus regimen vs. continued basal insulin therapy,
both in combination with metformin, in participants aged
≥18 years with a BMI ≤40.0 kg/m2 diagnosed with Type 2
diabetes for ≥6 months and treated for ≥3 months prior to
screening with once-daily basal insulin [insulin detemir,
insulin glargine U100 or neutral protamine Hagedorn
(NPH)] and metformin ≥1000 mg with or without other
oral antidiabetes drugs. Participants had an HbA1c of 59–
80 mmol/mol (7.5–9.5%) if taking metformin, or 59–
75 mmol/mol (7.5–9.0%) if taking metformin plus other
oral antidiabetes drugs at the screening visit.
At the start of an 8-week run-in period, participants
continued their once-daily basal insulin and metformin and
discontinued all other oral antidiabetes drugs. During run-in,
basal insulin dose was optimized using a treat-to-target
approach, with weekly adjustments to a pre-breakfast target
of 4.0–6.0 mmol/l (71–108 mg/dl). After the run-in period,
basal insulin dose was adjusted at the investigator’s
discretion.
Participants requiring further intensification [i.e. HbA1c
53–75 mmol/mol (7.0–9.0%) following the run-in period]
were randomized 1:1 to faster aspart in basal–bolus therapy
or to continue basal insulin-only therapy. Randomization
was stratified based on the type of basal insulin used (insulin
detemir, insulin glargine U100 or NPH). Participants ran-
domized to receive faster aspart self-adjusted the dose by
1-unit increments aiming for a pre-prandial or bedtime target
of 4.0–6.0 mmol/l (71–108 mg/dl).
Post hoc analysis population and outcomes
All participants included in the full analysis set were
considered for the post hoc analysis. Participants were
required to have baseline 1,5-AG information available for
inclusion (baseline was defined as the randomization visit
after basal insulin optimization). As 1,5-AG levels can
display substantial variation between individuals, partici-
pants were divided into subgroups based on a range of 1,5-
AG cut-off values (2, 3, 4, 5 or 6 lg/ml). Treatment
differences in change from baseline in HbA1c were estimated
for 1,5-AG subgroups below and above each cut-off value.
Statistical analysis
Change from baseline in HbA1c in subgroups above and
below each 1,5-AG cut-off value was analyzed using a
mixed-effects model for repeated measures (MMRM). All
calculated changes in HbA1c from baseline at weeks 6, 12
and 18 were included in the analysis. The model included a
What’s new?
• The onset 3 trial evaluated the efficacy and safety of
adding mealtime fast-acting insulin aspart to basal
insulin in people with Type 2 diabetes.
• This post hoc analysis of onset 3 indicates that low 1,5-
anhydroglucitol is predictive of basal–bolus treatment
effect.
• The findings suggest that 1,5-anhydroglucitol measure-
ments may be useful for identifying people with Type 2
diabetes who would most benefit from intensifying
insulin therapy, but further research is needed to
determine whether 1,5-anhydroglucitol adds clinical
utility beyond that of HbA1c.
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treatment-by-subgroup interaction, alongside the main
effects of treatment, subgroup (above/below cut-off value),
region (Asia, Europe, North America or South America) and
strata (insulin detemir, insulin glargine U100 or NPH), with
baseline HbA1c and baseline 1,5-AG as covariates. All effects
were nested within visit; an unstructured covariance matrix
was used to describe the variability for the repeated
measurements for participants. The P-value for the interac-
tion term was used to evaluate if the treatment effect was
different above vs. below the cut-off value. A P-value <0.05
was considered statistically significant.
Results
Baseline characteristics
Baseline characteristics in the onset 3 population were
similar between the basal–bolus therapy and basal insulin-
only treatment groups (Table 1) [9]. 42.4% (n = 100) of
participants were from Europe or North America. Of the
onset 3 population (n = 236), 234 participants had baseline
1,5-AG information available and were included in the post
hoc analysis of baseline characteristics (Table 2). Only
participants with post-baseline HbA1c data contributed to
the MMRM analysis (n = 232).
Association between baseline 1,5-AG and change from
baseline in HbA1c after 18 weeks of treatment
Figure 1 indicates a separation in HbA1c treatment difference
at week 18 between basal–bolus therapy and basal insulin-
only therapy at lower baseline 1,5-AG values. The difference
between the smoothing curves fitted to the scatter plot
demonstrates the larger treatment effect at lower baseline
1,5-AG compared with higher baseline 1,5-AG.
HbA1c treatment difference above vs. below 1,5-AG cut-off
values
The ETD in change from baseline in HbA1c between basal–
bolus therapy and basal insulin-only therapy was statistically
significantly greater in participants with baseline 1,5-AG
≤3 lg/ml (n = 34) vs. >3 lg/ml (n = 198) [ETD (95% CI):
1.53% (2.12; 0.94) vs. 0.82% (1.07; 0.57);
P-value for interaction = 0.03]. The ETD became more
pronounced when comparing participants with 1,5-AG
≤2 lg/ml (n = 15) vs. >2 lg/ml (n = 217) [ETD (95% CI):
2.26% (3.15; 1.36) vs. 0.85% (1.08; 0.62);
P-value for interaction = 0.003]. For cut-off values ≥4 lg/
ml, ETDs were numerically greater below the cut-off
compared with above, although the interaction terms were
not statistically significant (Fig. 2).
Baseline characteristics above and below 1,5-AG cut-off
values
Baseline characteristics of participants in the 3 lg/ml 1,5-AG
cut-off subgroups are shown in Table 2. Baseline character-
istics were similar between basal–bolus therapy and basal
insulin-only therapy within the two subgroups. Participants
in the ≤3 lg/ml subgroup had numerically higher mean
HbA1c, FPG and 2-h PPG (SMPG) at baseline compared with
participants in the >3 lg/ml subgroup [≤3 (n = 35) vs. >3 lg/
ml (n = 199): HbA1c, 68 vs. 62 mmol/mol (8.4 vs. 7.9%);
FPG, 8.2 vs. 7.4 mmol/l (147.7 vs. 133.7 mg/dl); 2-h PPG
(SMPG), 9.8 vs. 8.7 mmol/l (176.6 vs. 156.8 mg/dl)]. Body
weight, BMI and duration of diabetes were similar between
the two subgroups. The baseline characteristics of partici-
pants in the 2, 4, 5 and 6 lg/ml cut-off subgroups are
included in the supporting information for this article
(Table S1).
Discussion
In onset 3, addition and titration of mealtime faster aspart in
basal–bolus therapy effectively improved glycaemic control
in people with Type 2 diabetes, demonstrating the expected
superiority to basal insulin-only therapy for HbA1c and PPG
control [9]. However, in routine clinical practice, identifying
people with Type 2 diabetes who could most benefit from
intensifying treatment with basal–bolus therapy, and
Table 1 Baseline characteristics of the onset 3 population at
randomization [9]
Characteristic,
n, FAS
Faster aspart
in basal–bolus
therapy
(n = 116)
Basal
insulin-only
therapy
(n = 120)
Total
(n = 236)
Age, years 57.5 (9.9) 57.4 (8.5) 57.4 (9.2)
Gender, n (%)
Men 55 (47.4) 59 (49.2) 114 (48.3)
Women 61 (52.6) 61 (50.8) 122 (51.7)
BMI, kg/m2 30.4 (5.0) 31.1 (4.7) 30.8 (4.8)
Body weight, kg 82.2 (16.2) 85.1 (17.3) 83.7 (16.8)
Duration of
diabetes, years
10.9* (6.1) 11.8 (7.4) 11.3 (6.3)
HbA1c
mmol/mol 63 (8) 63 (7) 63 (8)
% 7.9 (0.7) 7.9 (0.7) 7.9 (0.7)
FPG
mmol/l 7.4 (2.4) 7.7† (2.9) 7.5 (2.6)
mg/dl 132.5 (43.5) 138.9 (51.4) 135.7 (47.7)
1,5-AG, lg/ml 8.2 (5.4) 7.7 (4.7) 7.9 (5.0)
Data are mean (SD) unless stated otherwise.
*n = 115; †n = 119.
The conversion factor used for glucose betweenmmol/l andmg/dl
was 0.0555.
1,5-AG, 1,5-anhydroglucitol; FAS, full analysis set; faster
aspart, fast-acting insulin aspart; FPG, fasting plasma glucose;
n, number of participants contributing to the analysis.
Reproduced and adapted from, with permission from John
Wiley and Sons, Rodbard HW et al. Diabetes Obes Metab
2017; 19: 1389–1396. © John Wiley and Sons 2017.
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intensifying in a timely manner, is a challenge. Indeed, a
recent study showed that only 30.9% of people with Type 2
diabetes with HbA1c ≥59 mmol/mol (≥7.5%) on basal
insulin had their treatment intensified after a median
3.7-year delay [11].
This post hoc analysis of onset 3 suggests that participants
with low baseline 1,5-AG (≤3 lg/ml) experienced an
increased benefit in HbA1c reduction with basal–bolus
therapy compared with participants with a higher baseline
1,5-AG (>3 lg/ml). Since all statistical models were adjusted
for HbA1c at baseline, the results can be interpreted as
indicating that if two individuals have similar HbA1c but one
has a low 1,5-AG then the latter may experience an increased
benefit in HbA1c reduction with basal–bolus therapy. It is
important to note that this analysis does not address the
question of whether 1,5-AG or HbA1c alone is more useful
for predicting response to adding basal–bolus therapy.
Instead, the results demonstrate, in a prospective setting,
the complementary value of 1,5-AG to HbA1c.
At baseline, participants in the 1,5-AG ≤3 lg/ml subgroup
had higher 2-h PPG (SMPG) across all meals compared with
participants in the 1,5-AG >3 lg/ml subgroup [SMPG:
9.8 mmol/l (176.6 mg/dl) vs. 8.7 mmol/l (156.8 mg/dl)].
While intensifying insulin therapy based on PPG values is
recommended, obtaining information on the prandial com-
ponent of hyperglycaemia requires frequently sampled blood
glucose measurements and relies on patient cooperation. In
contrast, 1,5-AG reflects glycaemic control over the previous
1–2 weeks and is more convenient to measure than a full
SMPG profile.
A previous post hoc analysis of people with Type 2
diabetes and suboptimal control with oral antidiabetes drugs
[HbA1c 54–63 mmol/mol (7.1–7.9%)] found that those with
baseline 1,5-AG <7.8 lg/ml achieved greater HbA1c reduc-
tion with initiation of insulin lispro mix 75/25 compared
with insulin glargine [12]. Although the study suggests that
1,5-AG may offer therapeutic insight when starting insulin
therapy, it did not find 1,5-AG to be predictive of treatment
effect.
While this is the first study to explore the use of 1,5-AG as
a predictor of the response to basal–bolus therapy, other
studies have shown that 1,5-AG is associated with the
Table 2 Baseline characteristics of participants included in the post hoc analysis by baseline 1,5-AG ≤3 lg/ml and >3 lg/ml
Characteristic
Baseline 1,5-AG ≤3 lg/ml Baseline 1,5-AG >3 lg/ml
Faster aspart in
basal–bolus
therapy (n = 19)
Basal
insulin-only
therapy (n = 16)
Total
(n = 35)
Faster aspart
in basal–bolus
therapy (n = 97)
Basal
insulin-only
therapy (n = 102)
Total
(n = 199)
Age, years 52.2 (10.1) 53.9 (7.4) 52.9 (8.9) 58.5 (9.6) 57.9 (8.3) 58.2 (8.9)
Gender, % men 63.2 56.3 60.0 44.3 48.0 46.2
Body weight, kg 85.3 (17.3) 80.3 (15.6) 83.0 (16.5) 81.5 (16.0) 85.8 (17.6) 83.7 (16.9)
BMI, kg/m2 29.9 (3.8) 29.6 (5.4) 29.8 (4.5) 30.5 (5.2) 31.3 (4.5) 30.9 (4.9)
Duration of diabetes, years 11.6 (5.2) 11.9 (7.6) 11.7 (6.3) 10.7 (6.3) 11.9 (7.4) 11.3 (6.9)
HbA1c
mmol/mol 68 (10) 68 (7) 68 (8) 62 (7) 63 (7) 62 (7)
% 8.4 (0.9) 8.3 (0.7) 8.4 (0.8) 7.9 (0.6) 7.9 (0.7) 7.9 (0.6)
FPG
mmol/l 8.0 (2.8) 8.4 (2.5) 8.2 (2.7) 7.2 (2.3) 7.6 (2.9) 7.4 (2.7)
mg/dl 144.3 (50.3) 151.9 (45.8) 147.7 (47.7) 130.1 (42.0) 137.1 (52.6) 133.7 (47.7)
2-h PPG (SMPG)
mmol/l 9.8 (2.1) 9.9 (2.1) 9.8 (2.0) 8.5 (1.8) 8.8 (1.7) 8.7 (1.7)
mg/dl 176.6 (37.8) 178.4 (37.8) 176.6 (36.0) 153.2 (32.4) 158.6 (30.6) 156.8 (30.6)
1,5-AG, lg/ml 2.2 (0.6) 2.1 (0.4) 2.1 (0.5) 9.3 (5.1) 8.6 (4.4) 9.0 (4.8)
Data are mean (SD) unless stated otherwise.
The conversion factor used for glucose between mmol/l and mg/dl was 0.0555.
Of the onset 3 population (n = 236), 234 participants had baseline 1,5-AG information available and were included in the post hoc analysis.
1,5-AG, 1,5-anhydroglucitol; faster aspart, fast-acting insulin aspart; FPG, fasting plasma glucose; n, number of patients contributing to the
analysis; PPG, postprandial plasma glucose; SMPG, self-measured plasma glucose.
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macro- andmicrovascular complications of diabetes. Analysis
of samples from ~10 000 people in the 20-year Atheroscle-
rosis Risk in Communities study found that, after adjustment
for HbA1c, 1,5-AG was associated with retinopathy and
chronic kidney disease in those with diagnosed diabetes [13].
Additionally, people with diabetes and 1,5-AG <6.0 lg/ml
had an increased risk of coronary heart disease, stroke, heart
failure or death compared with people with 1,5-AG ≥6 lg/ml
and no history of diabetes [14].
A limitation of this post hoc analysis is the small number
of participants in the baseline 1,5-AG subgroups; this is
reflected in the wide confidence intervals in the lower 1,5-
AG subgroups. In addition, due to its exploratory nature,
the analysis cannot identify an optimal cut-off value for
1,5-AG for predicting response to basal–bolus therapy.
Randomized clinical trials are needed to further evaluate
1,5-AG as a useful predictor of response to therapies
targeting PPG.
In conclusion, this post hoc analysis indicates that people
with Type 2 diabetes and low 1,5-AG have an added
treatment benefit with basal–bolus therapy compared with
those with higher 1,5-AG. This suggests that 1,5-AG may
be useful in identifying subgroups of people for whom
basal–bolus therapy is a particularly promising treatment
option. However, an added advantage of basal–bolus
therapy was observed only in a relatively small subgroup
of participants with very low 1,5-AG (≤3 lg/ml), and
further research is needed to clarify the clinical utility of
these findings.
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contributed to the MMRM analysis (n = 232).
1,5-AG, 1,5-anhydroglucitol; CI, confidence interval; ETD, estimated treatment difference; MMRM, mixed-effects model for repeated measures;
n, number of participants contributing to the analysis.
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